Deroy & Devereaux Private Investment Counsel Inc. grew its position in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 0.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 47,055 shares of the company’s stock after acquiring an additional 325 shares during the quarter. Deroy & Devereaux Private Investment Counsel Inc.’s holdings in Henry Schein were worth $3,430,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Henry Schein by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 15,432,001 shares of the company’s stock valued at $1,165,425,000 after acquiring an additional 260,537 shares during the last quarter. American Century Companies Inc. lifted its position in Henry Schein by 3.1% in the second quarter. American Century Companies Inc. now owns 5,484,286 shares of the company’s stock worth $351,543,000 after buying an additional 162,477 shares during the last quarter. Swedbank AB bought a new stake in Henry Schein in the first quarter worth $215,998,000. Nuance Investments LLC lifted its position in Henry Schein by 6.2% in the second quarter. Nuance Investments LLC now owns 1,863,333 shares of the company’s stock worth $119,440,000 after buying an additional 108,143 shares during the last quarter. Finally, Burgundy Asset Management Ltd. lifted its position in Henry Schein by 1.0% in the second quarter. Burgundy Asset Management Ltd. now owns 1,640,379 shares of the company’s stock worth $105,148,000 after buying an additional 16,476 shares during the last quarter. 96.62% of the stock is currently owned by institutional investors.
Henry Schein Stock Performance
Shares of Henry Schein stock opened at $70.23 on Friday. Henry Schein, Inc. has a 12 month low of $60.01 and a 12 month high of $82.63. The stock’s fifty day moving average price is $70.63 and its 200-day moving average price is $69.78. The firm has a market cap of $8.90 billion, a P/E ratio of 26.01, a P/E/G ratio of 2.03 and a beta of 0.86. The company has a current ratio of 1.55, a quick ratio of 0.90 and a debt-to-equity ratio of 0.46.
Wall Street Analysts Forecast Growth
HSIC has been the subject of a number of analyst reports. UBS Group lowered their price target on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Evercore ISI raised their price target on Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 8th. StockNews.com downgraded Henry Schein from a “hold” rating to a “sell” rating in a research report on Wednesday. Baird R W upgraded Henry Schein from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, JPMorgan Chase & Co. lowered their price target on Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $77.50.
Check Out Our Latest Stock Report on HSIC
Insider Activity at Henry Schein
In related news, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the sale, the senior vice president now owns 71,833 shares of the company’s stock, valued at $4,978,026.90. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.14% of the stock is owned by corporate insiders.
Henry Schein Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Articles
- Five stocks we like better than Henry Schein
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 3 Chip Stocks Expected to See Accelerating Sales Growth
- How to Invest in Blue Chip Stocks
- Super Micro Computer: Where Does it Go From Here?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.